Chronic Hepatitis News

Despite achieving cure with direct-acting antivirals, patients with chronic hepatitis C virus-related decompensated cirrhosis remain at risk for progression of portal hypertension, further decompensation and hepatocellular carcinoma.

Declines in serum hepatitis B virus RNA at the first and second year of treatment with nucleos(t)ide analogues correlated with risk for hepatocellular carcinoma and may serve as independent predictors of cancer development.

In a Healio video exclusive, Edward V. Loftus Jr., MD, warned that, despite being the smallest virus capable of causing human disease, hepatitis delta virus holds an outsized global impact as the most severe form of viral hepatitis.

Every year on July 28th, clinicians and researchers recognize World Hepatitis Day to bring awareness to one of the world’s deadliest but preventable viruses and continue efforts to meet the global goal of eliminating viral hepatitis by 2030

In a Healio video exclusive, Anu Osinusi, MD, MPH, reports that combination bulevirtide 10 mg with pegylated interferon alfa-2a for chronic hepatitis D virus infection resulted in the highest rates of undetectable HDV RNA through 48 weeks.

During Hepatitis Awareness Month, the CDC and allied public health organizations launched educational campaigns to raise awareness of viral hepatitis, deflate stigma around the infection and encourage early testing and vaccination.

The FDA has declined to approve Dynavax’s supplemental biologics license application for the expanded use of its four-dose hepatitis B vaccine regimen in adult patients on hemodialysis, according to a manufacturer’s press release.

Hepatitis C primary infection and reinfection incidences declined after the introduction of access to direct-acting antiviral hepatitis C treatments, researchers found.

Scaling up hepatitis C testing and treatment in prisons effectively reduced HCV incidence and was a cost-effective option compared with existing services, data from a study in Australian prisons showed.